New obesity drug KAI-7535: when should you take it?
NCT ID NCT07294898
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study looked at how a low-fat meal and taking the drug in the evening affect levels of KAI-7535 in the blood. Eighteen healthy adults with overweight or obesity took the drug under different conditions. The goal was to understand the best way to take it, not to test weight loss itself.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KAI-7535
- What this could lead to
- If successful, this could help determine the best way to take KAI-7535 for future weight-related treatments.
- What could go wrong
- This is a very early Phase 1 study with only 18 healthy participants, so results may not apply to patients or predict real-world effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anaheim Clinical Trials
Anaheim, California, 92801, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?